Figure 1.

Distribution of treatments at baseline by country. Each column illustrates the proportion of eligible patients (CHA₂DS₂-VASc Score≥2) across all cohorts in the named country who received either an NOAC (dark blue), a VKA (light blue), only AP therapy (dark green) and no AP or OAC (light green). Countries are sorted from left to right in order of increasing OAC use (the combined blue colours). The total numbers of patients from each country are shown in brackets after the country name. AP, antiplatelet treatment; NOAC, non-vitamin K oral anticoagulant; OAC, oral anticoagulation; VKA, vitamin K antagonist treatment.